ArticleJournal of inflammation research2025
Changes in Serum Bilirubin and Total Bile Acids During Biologic Therapy in Patients with Ulcerative Colitis: A Retrospective Study.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Relationship between serum total bilirubin levels and primary loss of response to Infliximab therapy in Crohn's disease patients.BMC gastroenterology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Ulcerative colitis (UC) requires new non-invasive serum biomarkers for assistance in monitoring due to the low rate of endoscopic follow-up. Previous research indicated reduced levels of serum indirect bilirubin (sIBIL), serum total bilirubin (sTBIL), and serum total bile acids (sTBAs) in UC patients. This study aims to assess their monitoring potential in UC during biologic therapy. Methods: We conducted a retrospective single-center study including 138 UC patients and 150 controls with normal colonoscopy results. The receiver operating characteristic (ROC) curve was used to assess diagnostic value of sIBIL, sTBIL, and sTBAs. Spearman correlation analysis was performed to assess the association between these biomarkers and the severity of both endoscopic findings and clinical symptoms in UC patients. Additionally, changes in serum biomarkers were analyzed in 72 UC patients during biologic therapy, with stratified analyses based on endoscopic remission status. Results: Patients with UC exhibited lower concentrations of sIBIL, sTBIL, and sTBAs compared to the controls ( Conclusion: sIBIL may be used as a valuable serum biomarker for the clinical diagnosis and the monitoring of response to biologics. Additionally, the change trend of sTBAs may provide reference value for monitoring UC biologic therapy. However, further studies are needed to analyze the changes in its internal composition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.